Novo Nordisk Introduces New Industry Resource for Information on Diabetes and Chronic Disease Inaugural Issue of the Novo Nordisk BlueSheet Addresses Health Reform
PRINCETON, N.J., March 30 /PRNewswire-FirstCall/ -- Novo Nordisk, a global healthcare company and leader in diabetes care, today announced the launch of the Novo Nordisk BlueSheet, a resource for information on diabetes and chronic disease, highlighting key issues in diabetes prevention, detection, treatment and care.
The first issue of the Novo Nordisk BlueSheet examines how legislation, advocacy and research can help change the way diabetes is funded and treated in the U.S. today. Each quarter, the Novo Nordisk BlueSheet will highlight key issues in diabetes from innovation in patient care to government investment in prevention and care to public education.
To read the Novo Nordisk BlueSheet, go to: http://press.novonordisk-us.com/bluesheet.
"Novo Nordisk is dedicated to changing how diabetes is treated, how it is viewed, and how the disease evolves in the future. But we cannot do it alone," said Jerzy Gruhn, president, Novo Nordisk Inc. "By stimulating a public dialog, we hope to act as a catalyst for change by encouraging action, influencing legislative policy and building advocacy for the prevention, detection, treatment and care of diabetes around the world."
About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic success. Headquartered in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchange in Copenhagen and its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk-us.com.
SOURCE Novo Nordisk